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Epidemiologic and clinical evidence points to an
increased risk for cancer when coupled with chronic
inflammation. However, the molecular mechanisms
that underpin this interrelationship remain largely
unresolved. Herein we show that the inflammation-
derivedcholesterol 5,6-secosterol aldehydes, athero-
nal-A (KA) and -B (ALD), but not the polyunsaturated
fatty acid (PUFA)-derived aldehydes 4-hydroxynone-
nal (HNE) and 4-hydroxyhexenal (HHE), induce
misfolding of wild-type p53 into an amyloidogenic
form that binds thioflavin T and Congo red dyes but
cannot bind to a consensus DNA sequence. Treat-
ment of lung carcinoma cells with KA and ALD leads
to a loss of function of extracted p53, as determined
by the analysis of extracted nuclear protein and in
activation of p21. Our results uncover a plausible
chemical link between inflammation and cancer and
expand the already pivotal role of p53 dysfunction
and cancer risk.INTRODUCTION
Inflammation, which functions at all three stages of tumor devel-
opment (initiation, progression, and metastasis), is a host’s
response to acute tissue damage (Balkwill and Mantovani,
2001; Coussens and Werb, 2002; Lu et al., 2006). It is generally
considered to play a role in tumor suppression by triggering an
anti-tumor immune response (Philip et al., 2004) but can also
stimulate tumor development (Balkwill and Mantovani, 2001;
Philip et al., 2004). In this regard many chronic inflammatory
conditions have associated neoplastic risk, e.g., the inflamma-
tory bowel diseases, ulcerative colitis and Crohn’s disease, are920 Chemistry & Biology 18, 920–927, July 29, 2011 ª2011 Elsevier Lincreased risk factors for colorectal carcinomas (Coussens and
Werb, 2002). Similarly, chronic lung inflammation or infection
has been associated with the development of lung cancer
(Borm and Driscoll, 1996; Keeley and Rees, 1997). Basic
research has shown that chronic inflammation appears to
contribute to tumor progression by establishing a long-term
milieu conducive to neoplasia (Coussens and Werb, 2002).
However, the precise mechanisms by which inflammation
achieves this remain to be determined.
The tumor suppressor protein p53 is a sequence-specific
transcription factor that functions to maintain the integrity of
the genome (Lane, 1992). On its induction/activation in response
to DNA damage, p53 promotes cell-cycle arrest in G1 phase
(Kastan et al., 1991) and apoptosis if DNA repair is not possible.
When p53 is inactivated, most commonly by a single missense
mutation or by binding of viral oncoproteins to p53, cell growth
can proceed without regulation, leading to tumor growth (Vogel-
stein and Kinzler, 1992). The critical nature of maintaining
functional p53 within the cell is emphasized by the fact that
mutations in the P53 gene are detected in 50% of human
cancers (Hollstein et al., 1991) and that 90% of these mutations
are in the core domain that is responsible for DNA binding
(Hernandez-Boussard et al., 1999). In addition to mutant p53
being inactive, several types of malignant and premalignant
tissues harbor a genetically wild-type but a transcriptionally
inactive form of p53, often localized in their cytoplasm, hinting
at epigenetic environmental triggers for p53 inactivation (Bosari
et al., 1995; Isaacs et al., 1998; Moll et al., 1992, 1995; Tominaga
et al., 1993).
Recently, we and others have discovered a process that is
being studied in the context of a number of disease-related
sporadic amyloidoses. We have shown that in vitro, certain
inflammatory-derived lipidic aldehydes, when adducted to proa-
myloidogenic proteins in their native state, can inducemisfolding
and aggregation of native protein sequences (Wentworth et al.,
2003; Zhang et al., 2004) (Figure 1). Thus, we have shown
that the cholesterol 5,6-seco-sterols atheronal-A and -B (KAtd All rights reserved
Figure 1. A Model for Lipid-Aldehyde Initiated p53 Inactivation
Scheme showing the concept of how membrane lipids, upon oxidation by reactive oxygen species (ROS), generate lipid-derived aldehydes such as KA, ALD,
HNE, andHHE, which then adduct reversibly to lysine residues of cellular proteins, such as p53, which can then lead to misfolding/aggregation and dysfunction.
The protein shown is a surface rendering of the p53 tetramerization domain (PDB reference 1tub), with surface lysines highlighted in blue.
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cholesterol by activated leukocytes during chronic inflammation,
accelerate the in vitro misfolding of apoB100, the protein compo-
nent of low-density lipoprotein (LDL), under physiologically
relevant conditions (Figure 1) (Wentworth et al., 2003). We and
others have also shown that 4-hydroxynonenal (HNE; a major
lipid peroxidation product of membrane lipids), KA, and ALD
accelerate the in vitro amyloidogenesis of b-amyloid peptides
(Ab 1-40 and 1-42), leading to prefibrillar assemblies of Ab
(Zhang et al., 2004) via a process that involves a reversible
site-specific modification of Ab (Scheinost et al., 2008), and
that KA and ALD accelerate the aggregation of a-synuclein
(Bosco et al., 2006), leading to fibrillar aggregates. In addition
we have shown that antibody light chains can be induced to
aggregate by lipid aldehydes, both to form amyloid or amor-
phous aggregates, in a process dependant upon the specific
aldehyde structure (Nieva et al., 2008). Most recently, we
have shown that adduction of KA and ALD to a murine prion
protein actually stabilizes the nonscrapie form of the prion and
prevents/inhibits scrapie formation (Scheinost et al., 2009),
showing that aldehyde adduction can be both proamyloidogenic
and antiamyloidogenic, depending on which protein and which
aldehyde are being studied.
Herein we report that the cholesterol-derived aldehydes KA
and ALD, but not the polyunsaturated fatty acid (PUFA)-derived
aldehydes HNE and 4-hydroxyhexenal (HHE), can induce amy-
loidogenesis of wild-type-p53 in a process that leads to a loss
of function of p53. Given the known associations between
inflammation and cancer, we see this as a potential newChemistry & Biology 18,chemical link between the two syndromes, and it further
highlights the potential for p53 misfolding, dysfunction, and
cancer risk.
RESULTS AND DISCUSSION
Lipid-Derived Aldehydes Adduct to p53
and Induce Misfolding
Quiescent incubation of full-length recombinant wild-type hexa-
histidine-tagged human p53 (His6-p53; 0.8 mg/ml) with the
inflammatory aldehydes KA, ALD, HNE, and HHE (each at
100 mM) in phosphate-buffered saline (PBS) (pH 7.4) with ethanol
(0.1% v/v) as a cosolvent leads to the acceleration in formation
of thioflavin-T (ThT)-positive aggregates with the cholesterol
seco-sterol aldehydes (time to half-maximal fluorescence: KA,
t5080min;ALD, t50100min), but not with the a,b-unsaturated
inflammatory aldehydes HHE and HNE, relative to vehicle (VEH;
PBS [pH 7.4], containing 0.1% v/v ethanol) (Figure 2A). The fluo-
rescence emission of the dye ThT is increased upon binding to
protein aggregates with a cross-b sheet structure (LeVine,
1999), either fibrillar or nonfibrillar in morphology (Hurshman
et al., 2004; Zhang et al., 2004). The time course of ThT fluores-
cence observed for the KA and ALD-initiated His6-p53 amyloid
formation, a rapid rise in ThT fluorescence to a plateau phase
with no lag phase, is indicative of a ‘‘seeded’’ or so-called down-
hill polymerization that is thermodynamically favored from the
outset (Ferrone, 1999), and is in line with what we have observed
previously for the atheronal-initiated polymerization of b-amyloid
and a-synuclein (Bosco et al., 2006; Zhang et al., 2004).920–927, July 29, 2011 ª2011 Elsevier Ltd All rights reserved 921
Figure 2. Lipid Aldehydes KA and ALD, but
NotHNE andHHE, Induce Amyloidogenesis
and Dysfunction of Recombinant His6-p53
(A) Graph of ThT fluorescence versus time during
quiescent incubation of His6-p53 (0.8 mg/ml) in
PBS (pH 7.4) with ethanol (0.1% v/v) cosolvent in
the presence of KA, ALD, HNE, or HHE (each at
100 mM). Data are reported as the mean fluores-
cence emission (excitation, 440 nm; emission,
485 nm) of duplicate experiments.
(B) Graph of KA concentration-dependent
(0–200 mM) quiescent aggregation of His6-p53
(0.8 mg/ml) in PBS (pH 7.4) with ethanol (0.1% v/v)
cosolvent, as measured by ThT fluorescence.
Data are reported as the mean fluorescence
(excitation, 440 nm; emission, 485 nm) of duplicate
experiments. Data are fitted to a third-order poly-
nomial using GraphPad Prism 4 for Macintosh.
(C) Optical microscope images (1003) obtained
under normal (upper) and cross-polarized (lower)
light of aggregates generated by incubation of
His6-p53 (0.8 mg/ml) with KA (25 mM) for 5 hr,
followed by centrifugation and staining with
Congo red (100 mM).
(D) FTIR spectra at times (0 min [yellow], 300 min
[blue], 800 min [green], and 1200 min [(red]) during
the quiescent aggregation of His6-p53 (0.5 mg/ml)
in D2O with KA (100 mM).
(E) Graph of functional p53 (as a percentage of
t = 0) versus time during the quiescent aggregation
of His6-p53 (0.8 mg/ml) in the presence of ALD
(50 mM) or VEH (ethanol 0.1% v/v). Data are
mean ± SEM of at least duplicate determinations.
Data for VEH are fitted to a linear regression
analysis (r2 = 0.992); data for ALD are fitted to
a single-phase exponential decay usingGraphPad
Prism 4.
(F) Graph of functional p53 (in ng/ml) versus ALD
during a 2 hr quiescent aggregation of His6-p53
(0.8 mg/ml) in the presence of ALD (0–80 mM).
Data are reported as the mean ± SEM of at least
duplicate determinations. Data are fitted to a
single-phase exponential decay using GraphPad
Prism 4.
See also Figure S1.
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to Amyloid Aggregates
The atheronal-induced aggregation of His6-p53 was studied in
some detail and is concentration dependent, exhibiting an
increase in the initial rate of ThT fluorescence as the ratio of
KA to p53 increases (Figure 2B). In addition the plateau
phase appears to be independent of ALD concentration but
is reached faster at higher concentrations of lipid aldehyde.
Incubation of His6-p53 with KA generates aggregates that
exhibit classic apple-green birefringence under polarizing
light, when stained with Congo red dye, further strengthening
the notion that incubation with cholesterol seco-sterols gener-
ates amyloid fibrillar p53 aggregates (Figure 2C). In addition
TEM analysis of His6-p53 incubated with ALD reveals ribbon-922 Chemistry & Biology 18, 920–927, July 29, 2011 ª2011 Elsevier Llike unbranched fibrillar assemblies (see Figure S1 available
online).
To gain insight into the structural transition from native wild-
type His6-p53 to its KA-induced misfolded state, we recorded
FT-IR spectra during the incubation of His6-p53 with KA (Fig-
ure 2D). In the absence of KA, the FT-IR of the native structure
of His6-p53 is unchanged. However, the FT-IR spectrum of
His6-p53 during incubation with KA (100 mM) at 37
C in PBS
(pH 7.4) exhibits a time-dependant shift of the amide-I absor-
bance band (t = 0min, lmax
1 = 1647 cm1; t = 300min, lmax
1 =
1635 cm1; t = 800 min, lmax
1 = 1626 cm1; t = 1200 min,
lmax
1 = 1609 cm1). Thus, the FT-IR spectrum of His6-p53
at t = 0 and 37C in PBS is dominated by a strong absorbance
at 1647 cm1, corresponding to a helices. As quiescenttd All rights reserved
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lower wave numbers, consistent with unfolding of a helices
and increased random peptide conformations. After incubation
for 1200 min, the absorbance is increased and is centered at
1609 cm1, characteristic of b strands in amyloid fibrils. There is
also an accompanying weaker absorbance band at 1683 cm1,
also indicative of b strand containing structures with strong
intermolecular hydrogen bonds, classic evidence of amyloid
formation.
The process by which amyloid fibrillization occurs from
natively folded proteins is constrained by aggregation from
partially unfolded intermediates (Uversky and Fink, 2004). There-
fore, proteins such as p53 require partial unfolding prior to the
onset of fibril formation. To explain the molecular basis of
amyloid fibril formation, it has been proposed that fibrillization
can occur when the rigid native structure of a protein is destabi-
lized, favoring partial unfolding and culminating in formation of
a partially unfolded conformation or intermediate (Dobson,
1999; Kelly, 1998). In the context of p53, very few studies have
been performed on the full-length protein; however, a number
of biophysical studies of the p53 tetramerization domain have re-
vealed that at acidic pH (4.0) and 37C, a mutant tetramerization
domain p53tet-R337H forms fibrils much faster than p53-tetwt,
as monitored by ThT fluorescence. Interestingly, the time-
dependent profiles of ThT fluorescence p53tet-R33H incubated
at pH 4.0 and KA-treated His6-p53 are remarkably similar.
Specifically, there is no apparent lag phase in the aggregation,
with peak ThT fluorescence occurring between 2 and 4 hr. There-
fore, the rationale proposed for the atheronal-induced aggrega-
tion of p53 in our work is in line with what has been proposed
for p53-tet-R337H, which involves partial unfolding followed by
assembly into proamyloid oligomers and fibrillization.
Atheronal-Misfolded p53 Cannot Bind to DNA
To investigate whether atheronal treatment of His6-p53 leads to
a loss of DNA binding, we utilized an ELISA that detects p53
when bound to a consensus duplex deoxyoligonucleotide
sequence. Thus, the ELISA is a primary readout of DNA-bound
p53 and does not detect p53 that is not bound to DNA. Quies-
cent incubation of His6-p53 (0.8 mg/ml) with ALD (50 mM) in
PBS (pH 7.4) leads to a time-dependant loss of DNA binding
(Figure 2E). Thus, incubation of His6-p53 for 30 hr with ALD
(50 mM) leads to an 85% drop in DNA-binding ability of p53,
as determined by ELISA, whereas incubation with VEH, under
the same conditions, leads to a drop of <10% in DNA binding.
The impact of atheronal incubation on His6-p53 function is also
concentration dependent. Incubation of His6-p53 (0.8 mg/ml)
for 24 hr with ALD (0–80 mM) leads to increased reduction in
p53-DNA binding (Figure 2F).
Interestingly, a comparison of the time-dependent changes
induced by incubation of His6-p53withALD on ThT fluorescence
and DNA binding reveals that the ThT fluorescence plateau is
reached at 240 min (Figure 2A), whereas the maximum impact
on DNA binding is not reached until 1300 min (Figure 2E).
Although the reasons for this disparity are unresolved, what is
clear is that ThT fluorescence is a precise measure of amyloid
structural changes, whereas the ELISA is a readout for any
structural change, amyloid and nonamyloid, that impairs DNA
binding. Therefore, an explanation of the two sets of data,Chemistry & Biology 18,ThT-fluorescence and DNA binding, is thatALD induces amyloid
changes in p53 structure first, followed by, or in concert with,
longer duration nonamyloid-like changes in p53, and it is the
nonamyloid changes that impact p53 DNA binding. This expla-
nation of amyloid and nonamyloid changes in His6-p53 induced
by ALD is supported by the fact that the solution turbidity of
ALD-treated p53, under conditions in Figure 2A, is visibly
increased after 24 hr, whereas at 4 hr (where ThT fluorescence
has reached a plateau), the solution is not visibly turbid.
Lipid-Derived Aldehydes Induce Misfolding
of p53 in Cultured Cells
To investigate the effect of lipid aldehydes on p53 in a cell-based
system, we treated the lung carcinoma cell line A-427, known
to upregulate wild-type p53 during UV or radiation-based
stress. Thus, cultured A-427 cells were exposed to g-irradiation
(5000 cGy) and then media were replaced with KA, ALD, HNE,
HHE (each at 20 mM), or VEH in media with 0.1% ethanol (cosol-
vent). The cells were then incubated at 37C for a further 24 hr.
After incubation of the cells with aldehydes, nuclear protein
was extracted, and the DNA binding of p53 was assessed by
ELISA as described vide supra (Figure 3A). The levels of p53
extracted from all treated cells were essentially unchanged;
however, the DNA-binding ability of p53 levels was significantly
different in all aldehyde-treated cells (p < 0.05), relative to VEH.
HHE-treated cells had an elevated level of functional p53 relative
to VEH (1.6 3 VEH; p < 0.05), and while the mechanism by
which this effect is under investigation, thismaybedue to a redis-
tribution of functional p53 from the cytosol to the nucleus. HNE-
treated cells have a significantly reduced level of DNA-binding
nuclear p53 relative to VEH (33% of VEH; p < 0.05), and given
that HNE does not induce p53 misfolding (Figure 2A), this hints
at an indirect off-target mechanism by which HNE is causing
p53 dysfunction. Previous work by Moos and coworkers
(Cassidy et al., 2006) has shown that certain endogenous
ab-unsaturated prostaglandin-derived aldehydes, such as
PGA1 and PGA2, can cause p53 misfolding in cells, by a process
that involves the chemical modification and inactivation of the
selenoprotein, thioredoxin reductase (TrxR) (Moos et al., 2000,
2003). Therefore, it seems plausible that HNE, which is an
ab-unsaturated aldehyde and is known to inactivate TrxR
(Cassidy et al., 2006), is inducing p53 dysfunction indirectly via
this mechanism.
The most dramatic disruption of p53 DNA binding in nuclear
extracts of A-427 cells occurs after incubation with the choles-
terol seco-sterols, KA and ALD (Figure 3A). There is very little
DNA binding of p53 in nuclear extracts from A-427 incubated
with KA and ALD (3.4%, p < 0.05 and 4.2%, p < 0.05 of VEH,
respectively). Extrapolation of the misfolding studies in Figure 2
to this p53 extraction data is complicated by potential off-target
effects in cells; however, it seems clear that the atheronals that
induce direct misfolding of p53 are far more impactful on
a mole for mole equivalence at disrupting functional p53 in cells
than HNE and HHE that have no direct effect on p53 misfolding.
Thus, whereas there may be indirect, off-target processes by
which certain aldehydes, such as HNE, PGA1, and PGA2, influ-
ence p53 function, the direct induction of p53 misfolding is
a potent mechanism by which inflammatory aldehydes can
modulate p53 binding to DNA.920–927, July 29, 2011 ª2011 Elsevier Ltd All rights reserved 923
Figure 3. Lipid Aldehydes Affect Wild-Type
p53 DNA Binding and p21 Activation in Cells
(A) Bar chart representing level of DNA binding
nuclear p53 extracted from A-427 cells incubated
at 37C for 24 hr with VEH (0.1% ethanol), HNE,
HHE, KA, or ALD (each at 40 mM) after receiving
a dose of g-radiation (5000 cGy). After the incu-
bation, nuclear extracts were taken, and total
protein (BCA), p53 (western blot), and functional
p53 (ELISA) were measured. Data are reported as
the mean ± SEM of triplicate determinations. Data
were analyzed using a Student’s two-tail t test
and were considered significantly different from
VEH (*) if p < 0.05.
(B) Upper view is a western blot analysis of p53
and p21 in nuclear protein extracts from A-427
cells before () and after (+) receiving g-radiation
(5000 cGy). Lower view is a western blot analysis
of p53 and p21 in nuclear protein extracts from
A-427 cells. Cells were incubated at 37C for 24 hr withALD (0–30 mM) after receiving a dose of g-radiation (5000 cGy). After the incubation, nuclear extracts were
taken, and total protein (BCA), p53, and p21 (western blot) were measured.
(C) Agarose gel analysis of p21 PCR DNA derived from p53 immunoprecipitation (IP) of A-427 genomic DNA. Lane 1 shows 100 bp ladder; lane 2, A-427 genomic
DNAwith p53 IP (after irradiation); lane 3, A-427 genomic DNAwith p53 IP (after irradiation and incubatedwithVEH for 20 hr); and lane 4, A-427 genomic DNAwith
p53 IP (after irradiation, ALD, 30 mM for 20 hr).
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and p53-Mediated Transcription
Genome damage usually increases the cellular levels of wild-
type p53 tumor suppressor and p53-dependent transcription
(Lane, 1992; Levine et al., 1991; Vogelstein and Kinzler, 1992;
Zambetti and Levine, 1993). Consistent with this phenomenon,
exposure of A-427 cells to g-irradiation (5000 cGy) leads to
a proportional increase in p53 protein and its transcriptionally
regulated protein, p21, relative to untreated cells (Figure 3B,
upper). Western blot analysis of p53 and p21 extracted from
A-427 cells that had been exposed to g-irradiation (5000 cGy)
and subsequently incubated with ALD (0–30 mM) reveals that
nuclear p53 levels remain unchanged with increasing levels of
atheronals (Figure 3B, middle). However, ALD treatment of
A-427 cells causes an atheronal concentration-dependent
reduction in the expression of p21 (Figure 3B, lower). This athe-
ronal-induced reduction in p21 expression is supported by
chromatin immunoprecipitation (ChIP) studies from atheronal-
treated A-427 cells. Purification of sheared chromatin, immuno-
precipitated by an anti-p53 antibody, followed by PCR of the
purified chromatin fragments, with p21 primers (forward 50-CC
AGCCCTTGGATGGTTT-30; reverse 50-GCCTCCTTTCTGTGCC
TGA-30) reveals that atheronal treatment leads to a reduction in
p21 expression (Figure 3C). These combined data suggest that
the atheronals do not directly impact the nuclear level of p53
but by inducing p53 misfolding, may cause a direct reduction
in p53 transactivation within the cell.
For the aldehydes KA and ALD to impact p53 misfolding in the
cells, they must come into direct contact with the protein and to
do this, have to either enter the nucleus or cytoplasm because
p53 exists in equilibrium between the nucleus and cytoplasm.
Although we have yet to perform an in-depth study of the traf-
ficking of the atheronals in cells, what we have shown previously
is that a fluorescently tagged ALD analog is rapidly taken up
(within 5 min) into cultured macrophages (J774), by a process
of diffusion, and traffics to all compartments of the cell, excluding
the nucleus (Takeuchi et al., 2006). Therefore, the cellular effects924 Chemistry & Biology 18, 920–927, July 29, 2011 ª2011 Elsevier Lwe observe on the A-427 cell line here are most likely initiated by
interaction between ALD and p53 in the cytoplasm, which then in
its misfolded form is either sequestered in the cytoplasm, pre-
venting its movement into the nucleus, or moves into the nucleus
where it is unable to bind to DNA.
The concentration of ALD that we show achieves clear DNA-
binding reduction in A-427 cells is 20 mM (Figure 2F). The
concentration of secosterols in the systemic circulation is
30 nM, whereas patients with inflammatory artery disease
have almost a log higher level of circulating aldehyde
(200 nM) (Wentworth et al., 2003). However, what is not yet
known are the effective local concentrations of atheronals in
tissues that are undergoing a chronic inflammatory response,
as would be the case in tumorigenic systems, which may be
much higher than in systemic circulation. An example of such a
difference is observed with HNE, which has nanomolar circu-
lating concentrations but cell membrane levels as high as
millimolar (Esterbauer, 1982; Esterbauer et al., 1990, 1991).
Therefore, the concentrations of ALD required to reduce p53
binding in cells are not beyond the plausible levels achievable
under the pathological syndrome being studied.
We propose that endogenous lipid-derived aldehydes are able
to adduct to surface-exposed lysine residues on wild-type
p53 protein, and in doing so specific aldehydes, such as the
cholesterol seco-sterol aldehydes (KA and ALD), but not the
PUFA-derived a,b-unsaturated aldehydes (HNE and HHE), can
induce a direct misfolding p53 event that is amyloidogenic.
This KA and ALD-induced misfolding event renders the p53
unable to bind to DNA in vitro, and exposure of cultured lung
carcinoma cells to the atheronals leads to a dramatic (p < 0.05)
reduction in the amount of DNA-binding nuclear p53 protein
(but not total nuclear p53) and a reduction in transactivation
of p21.
Finally, the observation that only certain aldehydes induce the
misfolding of p53 suggests that there is a molecular recognition
aspect to the aggregation process. This observation of molec-
ular recognition between an aggregation-prone protein and thetd All rights reserved
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initiated aggregation of b-amyloid peptides (Scheinost et al.,
2008). The importance of the recognition of the lipid’s structure
to protein aggregation is that this noncovalent recognition
should be able to be mimicked, leading to the development of
molecular chaperones that will protect p53 from the aldehyde-
initiated protein misfolding event and lead to potential new
anticancer drugs.
SIGNIFICANCE
What we show, to our knowledge, for the first time is that
direct modification of p53 by certain endogenous aldehydes
is sufficient to cause structural changes in p53 that may
contribute to epigenetic silencing. This direct inactivation
of p53 by cholesterol-derived aldehydes may be a hitherto
unknown chemical link between inflammation and cancer,
and may contribute in part to the known cancers where
wild-type inactivation of p53 has been reported, such as
breast cancer (Moll et al., 1992), neuroblastoma (Isaacs
et al., 1998; Moll et al., 1995), colon adenocarcinoma (Bosari
et al., 1995), and colon adenoma (Tominaga et al., 1993).
EXPERIMENTAL PROCEDURES
Cells and Proteins
The human A-427 lung carcinoma cell line carries wild-type p53. The recombi-
nant His6-p53 was purified from E. coli BL21 (DE3) transformed with pET-15b
plasmid containing the open reading frame for p53.
Recombinant His6-p53 Expression, Purification, and Refolding
The open reading frame encoding wild-type p53 was cloned by PCR into
pET-15b (Novagen) between NdeI and BamHI sites. PCR was performed on
pCMV-XL5-p53 from OriGene (Rockville, MD) using two primers: 50-GAG
AGA CAT ATG GAG GAG CCG CAG TCA GAT CC-30, and 50-GAG AGA GGA
TCC TCA TCA GTC TGA GTC AGG CCC TTC TG-30. The resulting plasmid,
pET-15b-p53, was transformed into E. coli BL21 (DE3) (Invitrogen) for
expression. The overnight culture from a single colony was diluted 1:100 into
1 liter of Luria Bertani media containing 100 mg/ml ampicillin, which then was
incubated with shaking at 37C until an OD600 of 0.6–0.8. Recombinant protein
expression was induced overnight at OD600nm of 0.4 by addition of 0.5 mM
isopropyl-b-D-thiogalactopyranoside (IPTG) at 25C. After centrifugation at
5000 rpm for 15 min, the cell pellets (2–4g) were frozen overnight at 20C.
More than 70% of the recombinant protein, expressed as detailed above,
deposits into inclusion bodies, and isolation was carried out after bacterial
cell lysis using 5 ml of BugBuster (Novagen) per gram of wet pellet, benzonase
nuclease, and EDTA-free protease inhibitors, followed by centrifugation at
5000 3 g for 30 min. The inclusion bodies were washed again with 10% Bug-
Buster to further remove cell debris and other proteins. For solubilization the
inclusion bodies were resuspended in 1 ml of 100 mM Tris-HCl, 6 M Guanidi-
niumChloride (GdmCl), 50mMDTT at pH 8.0. Renaturation of the recombinant
proteins isolated from the inclusion bodies was performed in refolding buffer
consisting of 50 mM sodium phosphate, 1 M L-arginine, 2 mM DTT, 0.2 mM
ZnCl2 at pH 8.0. The samples were incubated for 10 hr at 4
C. For large-scale
production (200 ml refolding buffer), pulse renaturation of p53 was followed
(solubilizate was added to the renaturation buffer six times with approximately
150 mg/ml per step and an interval of 90 min between each addition). After an
overnight dialysis against 50 mM NaPPhos, 5% (v/v) glycerol, 4 mM DTT,
pH 8.0 at 4C, the renatured proteins were precipitated using 30,000 MWCO
Vivaspin centricons (Sartorius).
Refolded protein samples were applied to the QIAGEN Ni-NTA Fast Start
2 ml purification columns. All fractions were collected and were analyzed
with 10% SDS-PAGE and western blot using a murine monoclonal antibody
for p53 (Abcam; catalog number ab1101).Chemistry & Biology 18,ThT Binding and Fluorescence of His6-p53 with Lipid Aldehydes
Recombinant His6-p53 (0.8 mg/ml) was incubated in at least duplicate with
lipid aldehydes KA, ALD, HNE, HHE (final concentration 100 mM), or VEH in
PBS (pH 7.4), and ethanol (0.1% v/v cosolvent) at 37C and in the presence
of Th-T (10 mM) in a 384-well microtiter plate (final assay volume 50 ml).
Time-dependent changes in the fluorescence (excitation, 440 nm; emission,
485 nm) of the assays were measured on a SpectraMax Gemini XS fluores-
cence detector (Molecular Devices, Union City, CA). Please note that all
the noncell-based assays reported in this study were performed with the
His6-p53 recombinant protein. However, we have performed ThT aggregation
assays with human wild-type p53 (Calbiochem, San Diego CA) and KA, and
the time course of fluorescence, both with VEH andKA (100 mM), was identical
to the wild-type p53 that we observed with our recombinant His6-p53 protein
construct. In addition, please note that for ease of assay, the ThT was present
during the aggregation assay. However, we have performed ThT aggregation
assays where assay aliquots are removed and added to a ThT solution (10 mM)
in PBS (pH 7.4), both with VEH andKA (100 mM), and the profiles were identical
to that we observed with ThT in the aggregation assay. Also note incubation
of ThT with VEH, KA, ALD, HNE, or HHE had no measurable effect on ThT
fluorescence excitation or emission.
Congo Red Binding and Birefringence
Wild-type native His6-p53 (0.7 mg/ml), prepared and purified as detailed
above, was incubated with KA (25 mM) in PBS (pH 8.0) with ethanol (4.0% v/v)
for 5 hr at room temperature (assay volume 100 ml) in a protein concentration
tube (Millipore). Congo red (100 mM in 1% ethanol in water) was added, and
themixture was allowed to stand at room temperature for 30min. The resultant
sample was then centrifuged (Millipore) at 3600 rpm for 30 min. The concen-
trated supernatant and aggregates were then added to a glass slide and
warmed at 37C for 10min. Glycerol and a coverslip were then applied. Aggre-
gates were analyzed under normal and phase-contrast light microscopy
conditions (1003 magnification; Olympus BX51 microscope). Images were
recorded on an Olympus MicroFire camera.
FTIR Studies
In a typical experiment, His6-p53 (0.5 mg/ml) in refolding buffer, prepared as
detailed above, was dialyzed overnight in deuterium oxide at 4C. Prior to
FTIR experiments, the binding activity of the His6-p53 was tested using the
ELISA-based TransBinding assay kit (Panomics, Redwood City, CA) detailed
below.
The misfolding process was started by addition of KA (100 mM final concen-
tration) or VEH to the solution of His6-p53 (0.5 mg/ml) in D2O with incubation
at room temperature. FTIR spectra were recorded throughout the assay at
room temperature on a Bio-Rad FTS 6000 FTIR machine, equipped with dia-
mond-attenuated total reflectance (ATR) with a He-Ne laser detector. Each
spectrum was the average of 100 spectra recorded over the course of
100 min. The raw absorbance data were exported into Microsoft Excel and
GraphPad Prism 4 for Macintosh for analysis.
Effect of ALD on DNA Binding of His6-p53
Wild-type His6-p53 protein (final concentration 0.8 mg/ml), prepared as
described above, was incubated in at least duplicate with lipid aldehyde ALD
(final concentration of 50 mM) or VEH in PBS (pH 7.4) and ethanol (0.1% v/v co-
solvent) at 37C. At times during the incubation, aliquots were removed, and
DNA binding was measured by the Panomics ELISA TransBinding kit. Data
are reported as the mean ± SEM of the functional p53 as a percentage (%) of
t = 0. Data analysis was performed using GraphPad Prism 4 for Macintosh.
Recombinant wild-type His6-p53 protein (final concentration of 0.8 mg/ml),
prepared as described above, was incubated in at least duplicate with lipid
aldehyde ALD at various concentrations (0–80 mM) in PBS (pH 7.4), and
ethanol (0.1% v/v cosolvent) at 37C. After 2 hr of incubation, DNA binding
of the p53 was measured by the Panomics ELISA described above. Data
are reported as the mean ± SEM of the functional p53 as nanogram per milli-
liter. Data analysis was performed using GraphPad Prism 4 for Macintosh.
Incubation of A-427 Cells with Lipid Aldehydes
Human lung carcinoma (ATCC; #HTB-53, A-427) cells were routinely cultured
in fetal calf serum (FCS; 10%) with minimum essential medium (MEM) and920–927, July 29, 2011 ª2011 Elsevier Ltd All rights reserved 925
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(0.1 mM), and sodium pyruvate (1 mM) to 80%–90% confluency in 75 cm2
flasks. A-427 cells were then exposed tog-irradiation (5000 cGy) froma cesium
source, media were replaced, and the cells were incubated for 24 hr in growth
medium. At this time, media were replaced with fresh media (15 ml) containing
KA, ALD, HNE, HHE (each at 40 mM), or VEH (ethanol, 0.1% v/v) in at least
duplicate and incubated for a further 24 hr at 37C. The cells were then pelleted
by centrifugation and washed with PBS (pH 7.4). Nuclear extracts were
obtained using a nuclear extraction kit (Panomics). Protein concentration of
the extracts was determined using a BCA protein assay kit (Pierce, Rockford,
IL), and p53 concentration was measured using western blot analysis. Quan-
tification of functional p53 was assessed by DNA binding using the Panomics
TransBinding p53 assay kit as detailed above. Five and 2.5 mg of nuclear
extract were added per well of the ELISA in duplicate for each condition,
respectively. The data for functional p53 (reported as mean ± SEM) were
determined by taking the raw absorbance data and interpolating from
a standard curve of known concentrations of wild-type p53 using GraphPad
Prism 4 for Macintosh.
ALD Treatment of A-427 Cells
A-427 cells were exposed to g-irradiation (5000 cGy) from a cesium source,
mediawere replaced, and the cells were incubated for 24 hr in growthmedium.
At this time, media were replaced with fresh media (15 ml) containing ALD
(40 mM) and VEH (ethanol, 0.1% v/v) in at least duplicate and incubated for
varying times up to 30 hr at 37C. At various times throughput the incubation,
cells were pelleted by centrifugation and washed with PBS (pH 7.4). Nuclear
extracts were obtained using a nuclear extraction kit (Panomics). Protein
concentration of the extracts was determined using a BCA protein assay kit
(Pierce), and p53 concentration was measured using western blot analysis.
Quantification of functional p53was assessed by DNA binding using the Pano-
mics TransBinding p53 assay kit as detailed above. Nuclear extract (5 and
2.5 mg) was added per well of the ELISA in duplicate for each condition,
respectively. The data for functional p53 (reported asmean ± SEM)were deter-
mined by taking the raw absorbance data and interpolating from a standard
curve of known concentrations of wild-type p53 using GraphPad Prism 4 for
Macintosh.
Measurement of p21 WAF Transcription
A-427 human lung carcinoma (ATCC; #HTB-53) cells were grown in FCS (10%)
MEM with L-glutamine (2 mM), sodium bicarbonate (1.5 g/l), nonessential
amino acids (0.1 mM), and sodium pyruvate (1 mM) to 80%–90% confluency
in 75 cm2 flasks. The cells were exposed to g-irradiation (5000 cGy) from
a cesium source, media were replaced, and the cells were incubated for
24 hr with VEH (0.1% ethanol) or ALD at 10–30 mM in at least duplicate. The
cells were then incubated for a further 16 hr. Nuclear extracts were obtained
from each condition using the Panomics Nuclear Extraction Kit (catalog
number AY2002). Protein concentration was determined for each extract
using the Pierce BCA protein assay kit (catalog number 23225). The nuclear
extracts were frozen at 80C and then analyzed by western blots. The
PVDF membranes were developed using the WesternBreeze Chromogenic
Immunodetection Kit (Invitrogen; catalog number WB7103). Total protein
was visualized with Ponceu S solution (Sigma-Aldrich; catalog number
P-7170). The primary antibodies, mouse anti-human p53 (BD; catalog number
554167) and mouse anti-human p21 (BD; catalog number 554262), were
diluted 1:500 and incubated overnight.
p21 ChIP Assay Protocol
A-427 cells were cultured to 80% confluence as detailed above. The cells were
exposed to g-irradiation (5000 cGy) from a cesium source, media were re-
placed, and the cells were incubated for 20 hr with VEH (0.1% ethanol) or
ALD at 30 mM in at least duplicate. Cells were harvested by trypsinization,
counted, and lysed using standard protocols. For chromatin shearing, cell
lysates were sonicated with a Misonix 3000 ultrasonicating bath at 4C (270
W, 20 cycles: 30 s pulse with 2 min cooling). A 1 kb DNA smear confirmed
successful shearing. For p53 immunoprecipitation, sheared lysates were
diluted 2:1 with antibody dilution buffer. A total of 5 mg/sample of biotinylated
goat anti-human p53 antibody was then added; please note that biotinylated
goat anti-IgG was added as a negative control. Samples were then incubated926 Chemistry & Biology 18, 920–927, July 29, 2011 ª2011 Elsevier Lfor 17 hr at 4C, with shaking at 250 rpm. Streptavidin agarose was then added
to the immunoprecipitation mixture, and the mixture was incubated for 30 min
at 4C with shaking, followed by addition of chelating resin and elution. For
purification and PCR of immunoprecipitated DNA, the immunoprecipitated
DNA was purified using QIAquick PCR Purification Kit (#28106), and PCR
was performed using p21 primers.
SUPPLEMENTAL INFORMATION
Supplemental Information includes one figure and can be found with this
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